NCT06020378

Hydroxychloroquine May be Beneficial for Preeclampsia

Hydroxychloroquine Treatment During Pregnancy is Associated With Lower Risk of Preeclampsia in Patients With Recurrent Spontaneous Abortion of Unknown Aetiology

• Status: Active Not Recruiting
• Phase: —
• Study type: Observational
• Enrollment: 462 (actual)
• Sponsor: RenJi Hospital · Academic / Other
• Sex: Female
• Age: —
• Healthy volunteers: Not accepted

Summary

The purpose of this research is to investigate the impact of hydroxychloroquine on the incidence of hypertensive pregnancy disorders in women with a history of recurrent spontaneous abortion (RSA).

Detailed description

Preeclampsia affects about 3-5% of all pregnancies and is estimated to cause at least 42 000 maternal deaths annually, remaining an important cause of death and complications for the mother and baby. However, no treatment yet has been found that affects disease progression except for termination of pregnancy which may cause iatrogenic preterm labor. Therefore, keenly sought for approaches to improving clinical outcomes in pre-eclampsia would be needed. Hydroxychloroquine (HCQ), an antimalarial drug, is commonly used in the treatment of pregnant women with RSA and has proven to be safe for both the mother and the fetus. Because of the antioxidant effect, anti-inflammatory effect, and vasculoprotective effect of HCQ, it has been thought to be beneficial in the prevention of preeclampsia. Therefore, we conducted a retrospective cohort study to evaluate the impact of HCQ treatment on the prevention of preeclampsia in RSA pregnancies.

Conditions

• Pre-Eclampsia

Interventions

Type	Name	Description
DRUG	Hydroxychloroquine	Hydroxychloroquine was administered during pregnancy

Timeline

• Start date: 2024-01-01
• Primary completion: 2026-07-01
• Completion: 2026-12-01
• First posted: 2023-08-31
• Last updated: 2025-04-24

Locations

1 site across 1 country: China